UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Clinical manifestations and diagnosis of peripheral spondyloarthritis in adults

Authors
David T Yu, MD
Astrid van Tubergen, MD, PhD
Section Editor
Joachim Sieper, MD
Deputy Editor
Paul L Romain, MD

INTRODUCTION

Peripheral spondyloarthritis (SpA) is the term used to describe patients with features of SpA whose symptoms and findings are predominantly or entirely peripheral rather than axial; these features include arthritis, which is predominantly of the lower limbs and/or asymmetric; enthesitis; and dactylitis. Patients included in this category, who have these findings in common, include those with psoriatic arthritis (PsA), reactive arthritis, SpA related to inflammatory bowel disease (IBD), and the subset of patients with such manifestations who do not meet established definitions for these forms of SpA. Patients with ankylosing spondylitis and non-radiographic axial SpA are not included within the peripheral SpA category, even if peripheral manifestations of musculoskeletal involvement are also present [1,2].

A clear distinction between the clinically defined subsets of patients with peripheral SpA is often lacking, other than for those with PsA. As examples, in a considerable number of patients skin manifestations of psoriasis do not occur until after the manifestation of rheumatic symptoms; preceding infections may be clinically asymptomatic, as an example, with Chlamydia; and IBD can also be asymptomatic when patients present with musculoskeletal symptoms [3,4].

An overview of the clinical manifestations, diagnosis, and differential diagnosis of peripheral SpA in adults will be presented here. The treatment of peripheral SpA; the classification of SpA; and the clinical manifestations, diagnosis, and treatment of ankylosing spondylitis, non-radiographic axial SpA, PsA, reactive arthritis, arthritis associated with IBD, and SpA in children are discussed in more detail separately. (See "Treatment of peripheral spondyloarthritis" and "Overview of the clinical manifestations and classification of spondyloarthritis" and "Clinical manifestations of ankylosing spondylitis in adults" and "Clinical manifestations and diagnosis of psoriatic arthritis" and "Diagnosis and differential diagnosis of ankylosing spondylitis and non-radiographic axial spondyloarthritis in adults" and "Spondyloarthropathy in children" and "Reactive arthritis" and "Assessment and treatment of ankylosing spondylitis in adults" and "Arthritis associated with gastrointestinal disease".)

EPIDEMIOLOGY AND NATURAL HISTORY

The global prevalence of spondyloarthritis (SpA), including axial and peripheral SpA, has been estimated at about 1 percent [5,6]; about one-quarter of SpA patients overall may exhibit predominantly peripheral SpA, although the incidence and prevalence of peripheral SpA alone has not been well-studied. Study results vary widely between different populations and ethnic groups, which can at least partly be explained by differences in the prevalence of human leukocyte antigen (HLA)B27. Other important contributors to these differences are heterogeneity in the populations analyzed, variation in the criteria used for case definition, and the number of participants approached and included in each study.

The prevalence of SpA was estimated to be 0.43 percent in a large population-based cohort representative of the French population, consisting of 20,625 employees of the French national electricity and gas company [7]; the proportion with peripheral SpA was 25 percent, consistent with a prevalence estimate within the French population of 0.11 percent.

              

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Thu Mar 24 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011; 70:25.
  2. Zochling J, Brandt J, Braun J. The current concept of spondyloarthritis with special emphasis on undifferentiated spondyloarthritis. Rheumatology (Oxford) 2005; 44:1483.
  3. Carter JD, Gérard HC, Espinoza LR, et al. Chlamydiae as etiologic agents in chronic undifferentiated spondylarthritis. Arthritis Rheum 2009; 60:1311.
  4. Van Praet L, Van den Bosch FE, Jacques P, et al. Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model. Ann Rheum Dis 2013; 72:414.
  5. Akkoc N. Are spondyloarthropathies as common as rheumatoid arthritis worldwide? A review. Curr Rheumatol Rep 2008; 10:371.
  6. Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken) 2012; 64:905.
  7. Costantino F, Talpin A, Said-Nahal R, et al. Prevalence of spondyloarthritis in reference to HLA-B27 in the French population: results of the GAZEL cohort. Ann Rheum Dis 2015; 74:689.
  8. Hukuda S, Minami M, Saito T, et al. Spondyloarthropathies in Japan: nationwide questionnaire survey performed by the Japan Ankylosing Spondylitis Society. J Rheumatol 2001; 28:554.
  9. Savolainen E, Kaipiainen-Seppänen O, Kröger L, Luosujärvi R. Total incidence and distribution of inflammatory joint diseases in a defined population: results from the Kuopio 2000 arthritis survey. J Rheumatol 2003; 30:2460.
  10. De Angelis R, Salaffi F, Grassi W. Prevalence of spondyloarthropathies in an Italian population sample: a regional community-based study. Scand J Rheumatol 2007; 36:14.
  11. Townes JM, Deodhar AA, Laine ES, et al. Reactive arthritis following culture-confirmed infections with bacterial enteric pathogens in Minnesota and Oregon: a population-based study. Ann Rheum Dis 2008; 67:1689.
  12. Söderlin MK, Börjesson O, Kautiainen H, et al. Annual incidence of inflammatory joint diseases in a population based study in southern Sweden. Ann Rheum Dis 2002; 61:911.
  13. Saraux A, Guillemin F, Guggenbuhl P, et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005; 64:1431.
  14. Boyer GS, Templin DW, Cornoni-Huntley JC, et al. Prevalence of spondyloarthropathies in Alaskan Eskimos. J Rheumatol 1994; 21:2292.
  15. Dougados M, van der Linden S, Juhlin R, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991; 34:1218.
  16. Mease P, Sieper J, Van den Bosch F, et al. Randomized controlled trial of adalimumab in patients with nonpsoriatic peripheral spondyloarthritis. Arthritis Rheumatol 2015; 67:914.
  17. D'Agostino MA, Olivieri I. Enthesitis. Best Pract Res Clin Rheumatol 2006; 20:473.
  18. Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A, et al. Assessment of enthesitis in ankylosing spondylitis. Ann Rheum Dis 2003; 62:127.
  19. Healy PJ, Helliwell PS. Dactylitis: pathogenesis and clinical considerations. Curr Rheumatol Rep 2006; 8:338.
  20. Sieper J, van der Heijde D, Landewé R, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis 2009; 68:784.
  21. Al-Amayreh IA, Zaidat BO. Ankylosing spondylitis in Northern Jordan. Saudi Med J 2000; 21:950.
  22. Rosenbaum JT. Characterization of uveitis associated with spondyloarthritis. J Rheumatol 1989; 16:792.
  23. Monnet D, Breban M, Hudry C, et al. Ophthalmic findings and frequency of extraocular manifestations in patients with HLA-B27 uveitis: a study of 175 cases. Ophthalmology 2004; 111:802.
  24. Van Praet L, Jacques P, Van den Bosch F, Elewaut D. The transition of acute to chronic bowel inflammation in spondyloarthritis. Nat Rev Rheumatol 2012; 8:288.
  25. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. J Clin Gastroenterol 1996; 23:29.
  26. De Keyser F, Baeten D, Van den Bosch F, et al. Gut inflammation and spondyloarthropathies. Curr Rheumatol Rep 2002; 4:525.
  27. Cuvelier C, Barbatis C, Mielants H, et al. Histopathology of intestinal inflammation related to reactive arthritis. Gut 1987; 28:394.
  28. Mielants H, Veys EM, Cuvelier C, et al. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint. J Rheumatol 1995; 22:2279.
  29. Eder L, Gladman DD. Psoriatic arthritis: phenotypic variance and nosology. Curr Rheumatol Rep 2013; 15:316.
  30. Baeten D, Breban M, Lories R, et al. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum 2013; 65:12.
  31. Robinson PC, Claushuis TA, Cortes A, et al. Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis. Arthritis Rheumatol 2015; 67:140.
  32. Cantini F, Nannini C, Cassarà E, et al. Uveitis in Spondyloarthritis: An Overview. J Rheumatol Suppl 2015; 93:27.
  33. Louthrenoo W. Rheumatic manifestations of human immunodeficiency virus infection. Curr Opin Rheumatol 2008; 20:92.
  34. Nguyen BY, Reveille JD. Rheumatic manifestations associated with HIV in the highly active antiretroviral therapy era. Curr Opin Rheumatol 2009; 21:404.
  35. Maganti RM, Reveille JD, Williams FM. Therapy insight: the changing spectrum of rheumatic disease in HIV infection. Nat Clin Pract Rheumatol 2008; 4:428.
  36. Winchester R, Bernstein DH, Fischer HD, et al. The co-occurrence of Reiter's syndrome and acquired immunodeficiency. Ann Intern Med 1987; 106:19.
  37. Njobvu P, McGill P. Human immunodeficiency virus related reactive arthritis in Zambia. J Rheumatol 2005; 32:1299.
  38. Njobvu P, McGill P, Kerr H, et al. Spondyloarthropathy and human immunodeficiency virus infection in Zambia. J Rheumatol 1998; 25:1553.
  39. Perez-Alamino R, Maldonado-Ficco H, Maldonado-Cocco JA. Rheumatic manifestations in inflammatory bowel diseases: a link between GI and rheumatology. Clin Rheumatol 2016; 35:291.
  40. Resnick D, Feingold ML, Curd J, et al. Calcaneal abnormalities in articular disorders. Rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and Reiter syndrome. Radiology 1977; 125:355.
  41. Olivieri I, Scarano E, Padula A, et al. Dactylitis, a term for different digit diseases. Scand J Rheumatol 2006; 35:333.
  42. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 Suppl 2:ii1.
  43. Collantes E, Veroz R, Escudero A, et al. Can some cases of 'possible' spondyloarthropathy be classified as 'definite' or 'undifferentiated' spondyloarthropathy? Value of criteria for spondyloarthropathies. Spanish Spondyloarthropathy Study Group. Joint Bone Spine 2000; 67:516.
  44. Rothschild BM, Pingitore C, Eaton M. Dactylitis: implications for clinical practice. Semin Arthritis Rheum 1998; 28:41.